Eiger Biopharmaceuticals (Celladon) Acquired, Nasdaq: EIGR
Developing a first-in-class gene therapy for patients with systolic heart failure.
Industry: Health Care
First Day Return: +2.3%
EIGR
Developing a first-in-class gene therapy for patients with systolic heart failure.
| IPO Data | |
|---|---|
| IPO Date | 01/29/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $44 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2000 |
| Employees at IPO | 15 |
| Website www.celladon.net | |
IPO News for Eiger Biopharmaceuticals (Celladon)
Eiger Biopharmaceuticals (Celladon) (EIGR) Performance
